{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:09:23Z","timestamp":1776092963929,"version":"3.50.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>Among patients with poly-refractory myeloma, autologous chimeric antigen receptor T-cell therapy offers exceptional promise. With the availability of bispecific antibodies, a total immunotherapeutic strategy in combination with chimeric antigen receptor T-cell therapy is now feasible.<\/jats:p>\n                    <jats:p>See related article by Fandrei et al., p. 38<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0236","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T09:51:34Z","timestamp":1732614694000},"page":"10-12","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Total (Immuno)Therapy: Version 2.0"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8919","authenticated-orcid":false,"given":"Susan","family":"Bal","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama."},{"name":"2O\u2019Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama."},{"name":"2O\u2019Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"2026041310200303000_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041310200303000_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.19227","article-title":"Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"204","author":"Bal","year":"2024","journal-title":"Br J Haematol"},{"key":"2026041310200303000_bib3","unstructured":"Fandrei\n            , . https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/doi.org\/10.1158\/2643-3230.BCD-24-0118."},{"key":"2026041310200303000_bib4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41409-023-02016-1","article-title":"CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas","volume":"58","author":"Baur","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2026041310200303000_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041310200303000_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"2026041310200303000_bib7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"Suppl 3","key":"2026041310200303000_bib8","doi-asserted-by":"crossref","first-page":"e15362d7","DOI":"10.1097\/01.HS9.0000967672.15362.d7","article-title":"S190: first results from the redirectt-1 study with teclistamab (TEC) + talquetamab (TAL) simultaneously targeting BCMA and GPRC5D in patients (PTS) with relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Mateos","year":"2023","journal-title":"HemaSphere"},{"key":"2026041310200303000_bib9","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S2152-2650(24)01929-3","article-title":"P-026 combined GPRC5D and BCMA-targeted T-cell redirecting therapy in the treatment of RRMM","volume":"24","author":"Godby","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041310200303000_bib10","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S2152-2650(24)01981-5","article-title":"P-078 prompt and profound responses with talquetamab in patients with heavily pretreated relapsed-refractory multiple myeloma\u2014another bridging therapy","volume":"24","author":"Shaikh","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0236\/3522568\/bcd-24-0236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/1\/10\/3530165\/bcd-24-0236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/1\/10\/3530165\/bcd-24-0236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:20:12Z","timestamp":1776090012000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/1\/10\/750797\/Total-Immuno-Therapy-Version-2-0Total-Immuno"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,26]]},"published-print":{"date-parts":[[2025,1,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0236","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}